Literature DB >> 21762016

Amnion-derived mesenchymal stromal cells show angiogenic properties but resist differentiation into mature endothelial cells.

Julia König1, Berthold Huppertz, Gernot Desoye, Ornella Parolini, Julia D Fröhlich, Gregor Weiss, Gottfried Dohr, Peter Sedlmayr, Ingrid Lang.   

Abstract

Mesenchymal stromal cells derived from the human amnion (hAMSC) currently play an important role in stem cell research, as they are multipotent cells that can be isolated using noninvasive methods and are immunologically tolerated in vivo. The objective of this study was to evaluate their endothelial differentiation potential with regard to a possible therapeutic use in vascular diseases. hAMSC were isolated from human term placentas and cultured in Dulbecco's modified Eagle's medium (DMEM) (non-induced hAMSC) or endothelial growth medium (EGM-2) (induced hAMSC). Induced hAMSC changed their fibroblast-like toward an endothelial-like morphology, and were able to take up acetylated low-density lipoprotein and form endothelial-like networks in the Matrigel assay. However, they did not express the mature endothelial cell markers von Willebrand factor and vascular endothelial-cadherin. Gene expression analysis revealed that induced hAMSC significantly downregulated pro-angiogenic genes such as tenascin C, Tie-2, vascular endothelial growth factor A (VEGF-A), CD146, and fibroblast growth factor 2 (FGF-2), whereas they significantly upregulated anti-angiogenic genes such as serpinF1, sprouty1, and angioarrestin. Analysis of protein expression confirmed the downregulation of FGF-2 and Tie-2 (27%±8% and 13%±1% of non-induced cells, respectively) and upregulation of the anti-angiogenic protein endostatin (226%±4%). Conditioned media collected from hAMSC enhanced viability of endothelial cells and had a stabilizing effect on endothelial network formation as shown by lactate dehydrogenase and Matrigel assay, respectively. In summary, endothelial induced hAMSC acquired some angiogenic properties but resisted undergoing a complete differentiation into mature endothelial cells by upregulation of anti-angiogenic factors. Nevertheless, they had a survival-enhancing effect on endothelial cells that might be useful in a variety of cell therapy or tissue-engineering approaches.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21762016     DOI: 10.1089/scd.2011.0223

Source DB:  PubMed          Journal:  Stem Cells Dev        ISSN: 1547-3287            Impact factor:   3.272


  23 in total

1.  Local renin-angiotensin system regulates hypoxia-induced vascular endothelial growth factor synthesis in mesenchymal stem cells.

Authors:  Yue Fan; Lulu Wang; Chao Liu; Hongyi Zhu; Lu Zhou; Yu Wang; Xiaowei Wu; Qingping Li
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

2.  Placental mesenchymal stromal cells derived from blood vessels or avascular tissues: what is the better choice to support endothelial cell function?

Authors:  Julia König; Gregor Weiss; Daniele Rossi; Karin Wankhammer; Andreas Reinisch; Manuela Kinzer; Berthold Huppertz; Dagmar Pfeiffer; Ornella Parolini; Ingrid Lang
Journal:  Stem Cells Dev       Date:  2015-01-01       Impact factor: 3.272

3.  Evidence for Kaposi Sarcoma Originating from Mesenchymal Stem Cell through KSHV-induced Mesenchymal-to-Endothelial Transition.

Authors:  Yuqing Li; Canrong Zhong; Dawei Liu; Wenjing Yu; Weikang Chen; Yan Wang; Songtao Shi; Yan Yuan
Journal:  Cancer Res       Date:  2017-10-24       Impact factor: 12.701

4.  Direct conversion of human amniotic cells into endothelial cells without transitioning through a pluripotent state.

Authors:  Michael Ginsberg; William Schachterle; Koji Shido; Shahin Rafii
Journal:  Nat Protoc       Date:  2015-11-05       Impact factor: 13.491

5.  Mesenchymal stem or stromal cells from amnion and umbilical cord tissue and their potential for clinical applications.

Authors:  Andrea Lindenmair; Tim Hatlapatka; Gregor Kollwig; Simone Hennerbichler; Christian Gabriel; Susanne Wolbank; Heinz Redl; Cornelia Kasper
Journal:  Cells       Date:  2012-11-12       Impact factor: 6.600

6.  Efficient direct reprogramming of mature amniotic cells into endothelial cells by ETS factors and TGFβ suppression.

Authors:  Michael Ginsberg; Daylon James; Bi-Sen Ding; Daniel Nolan; Fuqiang Geng; Jason M Butler; William Schachterle; Venkat R Pulijaal; Susan Mathew; Stephen T Chasen; Jenny Xiang; Zev Rosenwaks; Koji Shido; Olivier Elemento; Sina Y Rabbany; Shahin Rafii
Journal:  Cell       Date:  2012-10-18       Impact factor: 41.582

7.  Priming Mesenchymal Stem Cells with Endothelial Growth Medium Boosts Stem Cell Therapy for Systemic Arterial Hypertension.

Authors:  Lucas Felipe de Oliveira; Thalles Ramos Almeida; Marcus Paulo Ribeiro Machado; Marilia Beatriz Cuba; Angélica Cristina Alves; Marcos Vinícius da Silva; Virmondes Rodrigues Júnior; Valdo José Dias da Silva
Journal:  Stem Cells Int       Date:  2015-08-02       Impact factor: 5.443

8.  Stem cell transplantation for neuroprotection in stroke.

Authors:  Kazutaka Shinozuka; Travis Dailey; Naoki Tajiri; Hiroto Ishikawa; Yuji Kaneko; Cesar V Borlongan
Journal:  Brain Sci       Date:  2013-07-03

9.  An Update on Translating Stem Cell Therapy for Stroke from Bench to Bedside.

Authors:  Travis Dailey; Christopher Metcalf; Yusef I Mosley; Robert Sullivan; Kazutaka Shinozuka; Naoki Tajiri; Mibel Pabon; Sandra Acosta; Yuji Kaneko; Harry van Loveren; Cesar V Borlongan
Journal:  J Clin Med       Date:  2013-12       Impact factor: 4.241

10.  Amniotic Mesenchymal Stem Cells Can Enhance Angiogenic Capacity via MMPs In Vitro and In Vivo.

Authors:  Fei Jiang; Jie Ma; Yi Liang; Yuming Niu; Ning Chen; Ming Shen
Journal:  Biomed Res Int       Date:  2015-09-27       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.